ZA200505957B - Triazole compounds useful in therapy - Google Patents

Triazole compounds useful in therapy Download PDF

Info

Publication number
ZA200505957B
ZA200505957B ZA200505957A ZA200505957A ZA200505957B ZA 200505957 B ZA200505957 B ZA 200505957B ZA 200505957 A ZA200505957 A ZA 200505957A ZA 200505957 A ZA200505957 A ZA 200505957A ZA 200505957 B ZA200505957 B ZA 200505957B
Authority
ZA
South Africa
Prior art keywords
compound
formula
chloro
tetraaza
compound according
Prior art date
Application number
ZA200505957A
Other languages
English (en)
Inventor
Bryans Justin Stephen
Johnson Patrick Stephen
Ryckmans Thomas
Stobie Alan
Russell Rachel Jane
Wayman Christopher Peter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA200505957B publication Critical patent/ZA200505957B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
ZA200505957A 2003-07-23 2005-07-25 Triazole compounds useful in therapy ZA200505957B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
ZA200505957B true ZA200505957B (en) 2006-11-29

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505957A ZA200505957B (en) 2003-07-23 2005-07-25 Triazole compounds useful in therapy

Country Status (12)

Country Link
EP (1) EP1656183B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528171A (cg-RX-API-DMAC7.html)
AT (1) ATE380048T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412255A (cg-RX-API-DMAC7.html)
CA (1) CA2533177A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001702A1 (cg-RX-API-DMAC7.html)
GB (1) GB0317227D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05014200A (cg-RX-API-DMAC7.html)
TW (1) TW200510424A (cg-RX-API-DMAC7.html)
UA (1) UA79674C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005006899A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505957B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361B (zh) * 2023-09-28 2026-08-07 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CL2004001702A1 (es) 2005-05-13
CA2533177A1 (en) 2005-01-27
UA79674C2 (en) 2007-07-10
EP1656183A1 (en) 2006-05-17
ATE380048T1 (de) 2007-12-15
WO2005006899A1 (en) 2005-01-27
BRPI0412255A (pt) 2006-09-19
MXPA05014200A (es) 2006-07-03
TW200510424A (en) 2005-03-16
GB0317227D0 (en) 2003-08-27
JP2006528171A (ja) 2006-12-14
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
JP4084410B2 (ja) ヒスタミンh3受容体リガンドとして有用なテトラヒドロナフチリヂン誘導体
TW202115065A (zh) Kras突變蛋白抑制劑
WO2004074291A1 (en) Triazole compounds useful in therapy
JP2017522346A (ja) ブロモドメインに対して活性な化合物
EP2297112A1 (en) Pyrazole compounds as ccr1 antagonists
JP2008050365A (ja) H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体
CN103228660A (zh) Kat ii 抑制剂
JP2012131708A (ja) 4位置換ピリダジノン化合物及びp2x7受容体阻害剤
AU2008231543B2 (en) Pyrimido [4, 5-D] azepine derivatives as 5-HT2C agonists
JP2008531679A (ja) オキシトシンアンタゴニストとしての1,2,4−トリアゾール誘導体とその使用
US7456170B2 (en) Triazolobenzodiazepines and their use as vasopressin antagonists
US20060111416A1 (en) Octahydropyrrolo[3,4-C]pyrrole derivatives
US7442795B2 (en) Triazole compounds useful in therapy
EP1742950B1 (en) Pyrazolo[4,3-d] pyrimidines
MXPA06014025A (es) Derivados de triazol sustituidos como antagonistas de oxitocina.
KR100750028B1 (ko) 치료에 유용한 트리아졸 화합물
WO2007045989A1 (en) Pyridyl derivatives useful as h3 ligands
JP2009504628A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2008533192A (ja) オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
JPH107658A (ja) スルホニルウレイドピラゾール誘導体
HK1141024A (en) Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists
HK1144423A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands